Evaluation of a Pilot Breast Cancer Survivorship Care Plan in New Zealand
- Conditions
- Breast cancerBreast cancer survivorship care planCancer - Breast
- Registration Number
- ACTRN12612001175864
- Lead Sponsor
- Regional Cancer Treatment Service, MidCentral Health DHB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
1.Females or males with histologically diagnosed early breast cancer who have undergone surgery alone or just completed adjuvant chemotherapy and/or radiation therapy if this is required. Patients can be receiving adjuvant hormone therapy or adjuvant herceptin therapy.
2.Age >=18 yrs.
3.Able to read English proficiently.
4.Willing and able to comply with all study requirements.
5.Signed, written informed consent.
1.Patients who do not have a histological breast cancer diagnosis.
2.Patients with metastatic breast cancer.
3.Patients still receiving adjuvant chemotherapy or radiation therapy.
4.Life expectancy of less than 6 months.
5.Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the views of breast cancer patients regarding a pilot breast cancer SCP designed for a New Zealand context.[6 months after end of active breast cancer treatment (excluding adjuvant hormonal therapy or herceptin) using self-report questionnaire]
- Secondary Outcome Measures
Name Time Method To determine if there are particular areas of the pilot SCP that require modification.[6 months after end of active breast cancer treatment (excluding adjuvant hormonal therapy or herceptin) using self-report questionnaire];To determine if the method of providing the SCP to the patient is suitable.[6 months after end of active breast cancer treatment (excluding adjuvant hormonal therapy or herceptin) using self-report questionnaire];To determine levels of anxiety and depression in breast cancer patients 6 months after the completion of treatment.[6 months after end of active breast cancer treatment (excluding adjuvant hormonal therapy or herceptin) using Hospital Anxiety and Depression Scale in self-report questionnaire]